Table 1.

Characteristics of the patient cohort

Characteristic	Study cohort
Number of patients (samples before/depletion/early repletion/late repletion)	15 (15/12/10/10)
Sex, W/M	8/7
EDSS score at start of the study, median, IQR/range	2.5 ± 3.5
Age at start of study, y, mean ± SD	35.73 ± 8.91
Time since MS diagnosis, y, mean ± SD	10.76 ± 6.31
Observation time after initiation of anti-CD20 treatment, y, mean ± SD	2.68 ± 0.658
Last treatment before rituximab (cases)
Dimethylfumarate	2
Fingolimod	6
Glatiramer acetate	1
Natalizumab	2
Azathioprine	1
None (i.e., treatment naive)	3
Washout periods, mo, mean ± SD	5.42 ± 4.56
Prior treatments (cases)
Dimethylfumarate	2
Fingolimod	9
Glatiramer acetate	4
IFNβ-1a	6
IFNβ-1b	2
Natalizumab	6
Azathioprine	1
Cortisone (in last 6 mo before first anti-CD20 treatment)	4
None (i.e., treatment naive)	3
Patients with relapses after therapy initiation	1, yet with no MRI activity
Patients with EDSS deterioration after therapy initiation	1, yet after 19 mo since treatment initiation, without new MRI activity